StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
NASDAQ APVO opened at $0.41 on Thursday. Aptevo Therapeutics has a one year low of $0.28 and a one year high of $48.40. The stock has a 50 day moving average price of $0.56 and a 200-day moving average price of $3.05.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) EPS for the quarter, beating analysts’ consensus estimates of ($14.10) by $4.15. On average, sell-side analysts predict that Aptevo Therapeutics will post -8.86 earnings per share for the current fiscal year.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- Why Call Options Volume for These 2 Stocks Spiked Together
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 7/22 – 7/26
- ETF Screener: Uses and Step-by-Step Guide
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
